Athersys (ATHX) Receives Daily Coverage Optimism Score of 0.11

Media stories about Athersys (NASDAQ:ATHX) have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Athersys earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an impact on the company’s share price in the near term.

Here are some of the headlines that may have impacted Accern’s rankings:

Insider Buying and Selling by Quarter for Athersys (NASDAQ:ATHX)

A number of research analysts have recently commented on the stock. Maxim Group set a $9.00 price objective on shares of Athersys and gave the company a “buy” rating in a research report on Tuesday, May 16th. William Blair reaffirmed an “outperform” rating on shares of Athersys in a research report on Tuesday, March 28th. Finally, Zacks Investment Research raised shares of Athersys from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a research report on Tuesday, March 14th.

Athersys (ATHX) traded down 5.95% on Thursday, reaching $1.58. 1,433,525 shares of the company traded hands. The firm’s market cap is $175.88 million. Athersys has a 52-week low of $1.02 and a 52-week high of $2.35. The stock has a 50-day moving average price of $1.46 and a 200-day moving average price of $1.40.

Athersys (NASDAQ:ATHX) last posted its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. The business had revenue of $1.50 million during the quarter, compared to the consensus estimate of $0.45 million. Athersys had a negative net margin of 765.65% and a negative return on equity of 135.04%. The firm’s quarterly revenue was down 90.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.06 earnings per share. Analysts anticipate that Athersys will post ($0.26) earnings per share for the current fiscal year.

In other Athersys news, EVP John J. Harrington sold 36,000 shares of the stock in a transaction dated Friday, June 16th. The shares were sold at an average price of $1.45, for a total transaction of $52,200.00. Following the completion of the transaction, the executive vice president now owns 712,743 shares in the company, valued at $1,033,477.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 10.90% of the stock is owned by company insiders.

WARNING: This piece of content was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at

Athersys Company Profile

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply